Migraine affects 12% of the population and is more prevalent in women than in men, affecting 17% of women and 6% of men. An epidemiology study found that 53.7% of migraine patients have symptoms severe enough to cause activity restriction. 1 The cost to the United States due to management and loss of productivity from migraines is estimated to be as high as $17 million. 2
Current Treatment
Due to the decrease in activity associated with migraines, several drug classes have been used to prevent or reduce the number of headaches. Expert consensus recommended that migraine prophylaxis treatment be offered when patients experience more than 6 headaches per month, 4 headaches per month in patients with some impairment, or 3 headaches per month in patients with severe impairment or a need for bed rest. Prophylaxis can be considered with fewer headaches or less impairment. 1 A trial of lifestyle interventions, such as sticking with a regular schedule for sleeping and eating, exercising and avoiding migraine triggers, is usually tried first. If lifestyle interventions are not effective, pharmacotherapy is initiated. Drug classes with the most evidence for use in preventing migraines include antidepressants, beta-blockers, and anticonvulsants. Current prophylactic drugs decrease headaches by 50% in 50% to 75% of patients. 3 As the drugs are not 100% effective and cause adverse effects that affect compliance, new strategies have been studied to prevent headaches. 4
New Treatment Options
One pharmacologic strategy is to use an inhibitor of the calcitonin gene-related peptide (CGRP). CGRP is a neuropeptide found in both central and peripheral neurons. CGRP has both cerebral arteriolar dilating and pain modulation properties. An increase in CGRP is thought to decrease inhibitory mechanisms and increase the occurrence of migraine headaches. 4 As a class, the CGRP receptor inhibitors (Table 1) have reduced monthly migraine days by 50% and eliminated migraines in 10% to 20% of patients. 5 The onset of prophylaxis appears to be within days instead of months. The drugs also appear to be well tolerated, although no long-term safety and efficacy data are available. 6 data may be utilized. The information provided is meant to provide a way to assess the development status of a new drug and should not be used in making patient care decisions.
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